Ionis Pharmaceuticals Inc
IONS
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
178.1% downsideOvervalued by 178.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.64 Billion |
|---|---|
| Enterprise Value | $14.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.38 |
| Outstanding Shares | 164,874,000 |
Return
| Return on Equity | -49.67% |
|---|---|
| Return on Assets | -7.07% |
| Return on Invested Capital | -5376.75% |
Valuation & Multiples
| P/E Ratio | -38.62 |
|---|---|
| PEG | 104.3 |
| Price to Sales | 0.09 |
| Price to Book Ratio | 36.91 |
| Enterprise Value to Revenue | 0.11 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 4.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0228▲ 35.48% |
|---|---|
| Total Calls | 1,620,754▼ 6.90% |
| Total Puts | 1,657,700▲ 42.55% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.83%▲ 1.93% |
|---|---|
| Total Invested | $12.96B▼ 3.75% |
| Investors Holding | 520▼ 8.00% |
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...
Relevant Senate Committees
This committee directly influences corporate tax structures and capital investment credits through its analysis and scoring of tax legislation, which critically impacts Ionis Pharmaceuticals' financial performance.
This powerful committee controls taxation (influencing corporate valuations), trade, and entitlement spending (e.g., Medicare pricing), all of which directly affect Ionis Pharmaceuticals' profitability and market access for its drugs.
This committee allocates federal discretionary spending, directly influencing funding for scientific research (e.g., NIH) and healthcare programs that impact drug reimbursement and the R&D ecosystem.
This committee directly regulates the FDA (drug approval process) and the NIH (biomedical research funding), both of which are central to Ionis Pharmaceuticals' operations and success.
This committee oversees intellectual property laws (patents), which are critical for protecting pharmaceutical innovations, and antitrust laws, impacting potential mergers and market practices.